Health Canada approves new Eli Lilly GLP-1 pill for weight loss

Health Canada has approved Eli Lilly's Foundayo, a daily oral GLP-1 medication for weight loss and Type 2 diabetes management. This provides an alternative to the weekly injectable treatments currently dominating the market.
Why it matters
The introduction of an oral medication could significantly increase patient compliance and accessibility for weight-loss and diabetes treatments.
Health Canada has authorized a new GLP-1 medication for weight loss that is a pill taken every day, rather than weekly injections.
Eli Lilly’s Foundayo is approved for adults with obesity as well as those who are overweight and have at least one related medical problem, such as high blood pressure or sleep apnea.
In addition to promoting and maintaining weight loss, the pill is also approved to help treat Type 2 diabetes.
Eli Lilly also makes the injectable drugs Mounjaro and Zepbound, which contain the active ingredient tirzepatide. Tirzepatide acts on two receptors associated with insulin production and hunger: GLP-1 and GIP.
Competitor Novo Nordisk manufactures injectables Ozempic and Wegovy, which contain the active ingredient semaglutide. Semaglutide acts on GLP-1 receptors. Several other companies make generic semaglutide sold in Canada.
Also covering this story
One other newsroom covered this event. We read that version too.
Get smarter about the news
Sign up free for a feed built around what you actually care about, Dive Deeper research on any story, and the full text of every article.
Create free accountAlready have an account? Sign in